[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-363546-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-363546-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","the-impact-of-fulvestrant-on-estrogen-receptor-driven-chromatin-dynamics-in-breast-cancer-cells","The impact of fulvestrant on estrogen receptor-driven chromatin dynamics in breast cancer cells","","Epigenetic dysregulations are linked to diseases including breast cancer, where estrogen receptor-positive (ER+) tumors drive a large share of cancer-related deaths in women. This study examines how fulvestrant (FULV) and estradiol (E2) affect ER cistrome, chromatin accessibility, gene transcription, and H3K27ac patterns in ER+ breast cancer cell lines. Using CUT&Tag, E2 increases accessibility, transcription, and H3K27ac at ER sites, whereas FULV preserves transcription but elevates H3K27ac at a subset, revealing decoupling between acetylation and transcriptional output.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/the-impact-of-fulvestrant-on-estrogen-receptor-driven-chromatin-dynamics-in-breast-cancer-cells/363546/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/the-impact-of-fulvestrant-on-estrogen-receptor-driven-chromatin-dynamics-in-breast-cancer-cells/363546.png","ImageObject",300,407,{"name":42,"@type":43},"Aran","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-30","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",16,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the study’s main goal regarding fulvestrant and estradiol?","Question",{"text":63,"@type":64},"To investigate how fulvestrant (FULV) and estradiol (E2) affect ER binding programs, chromatin accessibility, gene transcription, and genome-wide H3K27ac patterns in ER+ breast cancer cell lines.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does estradiol (E2) change chromatin accessibility and transcription?",{"text":68,"@type":64},"E2 promotes ER recruitment to DNA and increases chromatin accessibility, transcriptional activation, and H3K27ac levels at ER binding sites.",{"name":70,"@type":61,"acceptedAnswer":71},"Why is fulvestrant described as not completely inert in this study?",{"text":72,"@type":64},"Although FULV does not significantly alter chromatin accessibility or transcription, it induces increased H3K27ac at a subset of ER binding sites, indicating distinct epigenetic effects beyond simple transcriptional silence.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},363546,1790190803,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":33,"preview_urls":147},137455076865,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Barlier etal. Epigenetics & Chromatin (2026) 19:22 Epigenetics & Chromatin  \n[https://doi.org/10.1186/s13072-026-00667-0](https://doi.org/10.1186/s13072-026-00667-0)  \nRESEARCH Open Access  \nThe impact offulvestrant on estrogen  receptor-driven chromatin dynamics in breast cancer cells  \nCéline Barlier 1, Mathias Simplicien 1, Ana Hermoso 1, Anais Pourrat 1, Elsa Moreau 1, Célia Fontana2, Aurelia Del herme2, Natalie Daluege3, Gurpreet Bharaj3, Cibele de Oliveira3, Alexander Vogt3, Vincent Piras 1, Coral ie Hoareau-Aveil la 1, Gaylor Boulay 1† and Isabel Paiva 1*†  \nAbstract  \nBackground Epigenetic dysregulations are linked to several diseases, including cancer. Among them, breast cancer is the second leading cause of cancer-related deaths in women, with 50% of mortal ities attributable to estrogen receptor-positive (ER +) tumors. Endocrine therapies targeting the ER such as Tamoxifen, Fulvestrant (FULV) and Aromatase inhibitors are widely used in the clinic. FULV has been shown to fully antagonize ER activity mainly by promoting rapid ER degradation and elimination. However, recent studies show that FULV-bound ER can still translocate to the nucleus and bind DNA, although it appears transcriptionally inert.  \nResults In this study, we aimed to further investigate the effects of FULV and Estradiol (E2), the natural ER ligand, on ER cistrome, chromatin accessibility, gene transcription, and H3K27ac genome-wide patterns in ER + breast cancer cell lines. Using the innovative CUT&Tag technology, we confirmed that both E2 and FULV promote ER recruitment to DNA, with E2 increasing chromatin accessibility, transcriptional activation, and H3K27ac levels at ER binding sites. In contrast, FULV does not significantly alter chromatin accessibility or transcription but is not completely inert, as it induces increased H3K27ac at a subset of ER binding sites. These observations indicate a decoupling between histone acetylation and transcriptional output under FULV treatment.  \nConclusions This study provides new insights into the mechanistic impact of FULV on ER activity, highlighting its ability to modulate H3K27ac dynamics even in the absence of transcriptional changes. These findings underscore the complexity of ER signaling and further suggest that FULV’s therapeutic effects may extend beyond simple antagonism of ER activity.  \nKeywords CUT&Tag, Estrogen Receptor, H3K27ac, ATAC-seq, Epigenetics, Chromatin landscape, Estradiol, Fulvestrant, Breast cancer  \n†Gaylor Boulay and Isabel Paiva have equal contribution.  \n*Correspondence:  \nIsabel Paiva [Isabel.paiva@evotec.com](Isabel.paiva@evotec.com)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons.org/l](vecommons.org/l)icenses/by-nc-nd/4.0/.  \nBarlier et al. Epigenetics & Chromatin (2026) 19:22 Page 2 of 15  \nGraphical abstract  \nSchematic overview illustrating the differential effects of E2 and FULV ER function in ER⁺ breast cancer cells: Upon E2 bind","cbCaipXunPYcP1ri","https://ap.wps.com/l/cbCaipXunPYcP1ri","pdf",2701466,15,"English","# Abstract\n## Background\n## Results\n## Conclusions\n# Graphical abstract\n# Background","[{\"question\":\"What was the study’s main goal regarding fulvestrant and estradiol?\",\"answer\":\"To investigate how fulvestrant (FULV) and estradiol (E2) affect ER binding programs, chromatin accessibility, gene transcription, and genome-wide H3K27ac patterns in ER+ breast cancer cell lines.\"},{\"question\":\"How does estradiol (E2) change chromatin accessibility and transcription?\",\"answer\":\"E2 promotes ER recruitment to DNA and increases chromatin accessibility, transcriptional activation, and H3K27ac levels at ER binding sites.\"},{\"question\":\"Why is fulvestrant described as not completely inert in this study?\",\"answer\":\"Although FULV does not significantly alter chromatin accessibility or transcription, it induces increased H3K27ac at a subset of ER binding sites, indicating distinct epigenetic effects beyond simple transcriptional silence.\"}]","The impact of fulvestrant on estrogen receptor-driven chromatin dynamics in breast cancer cells | PDF",1790151762,38,[148,152,156,160],{"page_no":22,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/737ba17ad6b11408c426bc27c72f7248.webp",983,1310,{"page_no":26,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e4f99af05afd0f3fb0c29d10534ace12.webp",982,1309,{"page_no":30,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/da438b648e6fe64c422f31009f650c8f.webp",981,1308,{"page_no":33,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/996821caf1dc3b98c4cdaffea34bcfd7.webp",980,1306]